Bangalore, Sep 21 (UNI) Biocon Ltd, India's premier biotechnology company, today presented the ''promising'' results of phase one studies of its oral insulin product, IN-105, at the European Association for Study of Diabetes (EASD) meeting at Amsterdam, based on which the company will develop the molecule through further clinical trials.
According to a company release here, the studies were conducted on healthy volunteers, who had been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on Novel therapies.
The IN-105 was a novel analog of insulin. The product had special properties that made it feasible for delivery in tablet form stable at room temperature.
Commenting on the presentation, Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said '' This is indeed an encouraging step towards our efforts of bringing an oral insulin to diabetic patients across the world. The IN-105 promises to be a significant value differentiator in Biocon's quest for global leadership in the insulin segment.'' Besides being a needle-free insulin, this method allowed IN-105 to be delivered in to the body in a way the pancreas released insulin.
This was in contrast to all the other known methods of delivery, including inhaled insulin, which brought in insulin from the periphery into circulation.
The company had carried out all the development for this molecule, including clinical development, at its facilities here.
It had recently obtained approval from the Swedish medical authorities to carry out the phase one human clamp studies for this molecule in Sweden, the first such clinical trial outside India for IN-105.
The trial would be carried out at the Karolinska Institute clinical research unit in Sweden, focussing on obtaining more pharmacological understanding of the molecule's mode of action, the release said.